IMAX CORP 8-K

What Happened IMAX Corporation (IMAX) filed an 8-K reporting that CEO Richard Gelfond, who was placed on a temporary medical leave of absence (previously announced March 30, 2026), will be temporarily replaced. On April 16, 2026 the Board appointed Robert D. Lister, the Company’s Chief Legal Officer and Senior Executive Vice President, to serve as interim principal executive officer (PEO) in addition to his current duties until May 1, 2026, when Mr. Gelfond is expected to resume the role.

Key Details

• Appointment date: April 16, 2026; interim term: through May 1, 2026.
• Interim PEO: Robert D. Lister (Chief Legal Officer & Senior EVP).
• Compensation: Mr. Lister will receive no additional compensation for the interim role.
• Corporate filings referenced: Biographical info for Mr. Lister is in IMAX’s definitive proxy (Schedule 14A) filed April 25, 2025. No new agreements, arrangements, or related-party transactions were reported in connection with the appointment.

Why It Matters This 8-K notifies investors of a short-term leadership change that maintains executive continuity while the CEO is on medical leave. The appointment appears administrative and temporary — there are no new compensation commitments or contractual changes disclosed — suggesting limited direct financial impact. Investors should view this as a governance update that clarifies who is authorized to act as the company’s principal executive officer during the specified period.